Figure 1IL28B rs12979860 RFLP-PCR genotyping. Lane L, DNA marker; Lane No. 1 is genotype TT (89 bp, 118 bp, and 183 bp), Lane No. 2 is genotype CC (25 bp, 89 bp and 183 bp), and Lane No. 3 is genotype CT (25 bp, 89 bp, 118 bp, and 183 bp).
Figure 2IL28B rs12979860 ARMS-PCR genotyping. Lane L. DNA marker; Lane No. 1 is genotype CT (326 bp and 443 bp), Lane No 2 is genotype CC (326 bp), and Lane No. 2 is genotype TT (443 bp).
Table 1Characterization, clinical, and virological properties of Iranian patients with CHC before anti-viral therapy with pegylated interferon-α2a/ribavirin.
Variables
|
Patients
|
HCV genotype |
1a |
3a |
Total |
p
|
No. (%) |
51 (51) |
49 (49) |
100 (100) |
|
Age (y) |
52.8 ± 4.7 |
51.7 ± 4.6 |
52.2 ± 4.6 |
0.259 |
Laboratory parameters |
AST (IU/L) |
261.3 ± 203.8 |
217.3 ± 191.6 |
239.3 ± 197.7 |
0.310 |
ALT (IU/L) |
274.0 ± 230.1 |
227.2 ± 228.3 |
250.6 ± 229.2 |
0.269 |
ALP (IU/L) |
692.3 ± 487.7 |
618.7 ± 397.6 |
655.5 ± 442.6 |
0.411 |
HCV viral load (IU/mL) |
4.9 × 106 ± 2.5 × 106
|
3.7 × 106 ± 2.2 × 106
|
4.3 × 106 ± 2.4 × 106
|
0.018 |
Table 2Analysis of IL28B rs12979860 polymorphisms in 100 patients with chronic hepatitis C virus genotype 1a and 3a using three different methods.
Method |
IL28B locus rs12979860
|
Cost |
Turnaround time |
CC (%) |
TT (%) |
CT (%) |
PCR-RFLP |
23 (23) |
11 (11) |
66 (66) |
US$4.70 |
6 h 45 min |
ARMS-PCR |
23 (23) |
11 (11) |
66 (66) |
US$3.10 |
2 h 40 min |
Direct sequencing |
23 (23) |
11 (11) |
66 (66) |
US$16.20 |
2 d |
Table 3Relationship between baseline demographic, clinical, virological characteristics and sustained virological responders with rs12979860 IL28B polymorphisms.
IL28B
|
rs12979860
|
Variable |
CC |
CT |
TT |
p
|
HCV genotype (1a/3a) |
10/13 |
35/31 |
6/5 |
0.710 |
Baseline viral load (IU/mL) |
3.3 × 106 ± 1.7 × 106
|
4.6 × 106 ± 2.5 × 106
|
4.5 × 106 ± 2.4 × 106
|
0.127 |
AST (IU/L) |
243.4 ± 240.1 |
253.0 ± 183.3 |
239.7 ± 206.9 |
0.661 |
ALT (IU/L) |
248.8 ± 245.9 |
262.2 ± 217.3 |
251.1 ± 213.3 |
0.689 |
ALP (IU/L) |
586.4 ± 360.7 |
558.7 ± 481.6 |
656.3 ± 356.0 |
0.569 |
SVR |
18 |
34 |
4 |
0.032∗
|
Non-SVR |
5 |
32 |
7 |
Table 4Relationship between virus genotype and SVR.
Patient features |
SVR |
Non-SVR |
Total |
p
|
No. of patients (%) |
56 |
44 |
100 |
— |
HCV genotype |
1a |
18 (35.3) |
33 (64.7) |
51 (100) |
< 0.001∗
|
3a |
38 (77.5) |
11 (22.5) |
49 (100) |
Table 5Results of multivariate regression analyses of the factors associated with sustained virological response in patients with HCV infection.
Characteristic |
p
|
OR |
95% CI |
HCV genotype |
<0.001†
|
7.42 |
2.605–21.105 |
Baseline viral load (IU/mL) |
0.327 |
1.00 |
1.000–1.000 |
IL28 (CC)†
|
0.067 |
1 |
|
IL28(TT) |
0.030b
|
7.86 |
1.225–50.511 |
IL28(CT) |
0.048b
|
4.08 |
1.010–16.524 |